Yourgene Health PLC Appointment of VP of Sales North America
March 17 2021 - 3:00AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
17 March 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Appointment of VP of Sales North America
Strategic hire to expand Yourgene's commercial footprint in
North America
Manchester, UK - 17 March 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces it has
appointed Scott Sargent as Vice President of Sales North America
with immediate effect, to support the Group's plans to expand and
grow its commercial footprint in the North American market,
following the acquisition of Coastal Genomics in August 2020.
Scott brings over 25 years of industry experience, having held
senior executive roles at large multinationals, most recently as
Director of Sales for Clinical Genomics for QIAGEN in the US and
Canada, where he led a commercial team selling into the Next
Generation Sequencing (NGS), PCR and sample extraction clinical
laboratory market. Scott's team grew 2019 NGS library preparation
sales by +25% over the previous year and total sales by +6% (to
$44M USD) over the previous year. Prior to this, Scott held senior
commercial roles at Illumina, where he was responsible for leading
business development for the market segments of rare disease and
reproductive health testing in the US / Canada. Scott also has
managed complex distributor relationships and sold extensively in
the PCR clinical market for Luminex Corporation and Roche
Diagnostics.
Scott will be responsible for building a North American
commercial team and working closely with the Coastal Genomics team
to help enable the Ranger Technology to win additional customers
across the blue-chip life-science companies, academic research
institutes and clinical molecular diagnostic organizations. This
innovative and automated sample preparation technology facilitates
efficiency and reproducibility across different applications
including NIPT, liquid biopsy for cancer detection and disease
monitoring, along with routine quality control for NGS
workflows.
A key focus for Scott will be to leverage the Group's modular
NGS analysis framework, Flex(TM) Analysis Software, and its size
selection technology (Yourgene QS250) to the NIPT and oncology
market in North America. The NIPT market is expanding following the
recent guidelines from the American College of Obstetricians and
Gynecologists (ACOG) recommending NIPT for all pregnant mothers,
not just those at high risk.
Commenting, Lyn Rees, CEO of Yourgene, said : "We welcome Scott
to the Group at this pivotal time of commercial growth in a key
geographic market. Scott's extensive industry experience, network
and track record will undoubtedly be an asset to the Group going
forward as we progress our expansion in the US diagnostics market,
which is the largest in the world."
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAFDKFDEFEAA
(END) Dow Jones Newswires
March 17, 2021 03:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
